Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease
NCT ID: NCT02528799
Last Updated: 2018-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
38 participants
INTERVENTIONAL
2015-08-31
2017-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nexvax2 DQ2.5 Homozygotes (Cohort 1)
Nexvax2 by ID injections for a total of 14 doses over 46 days.
Nexvax2
Nexvax2 intra-dermal injections twice weekly
Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)
Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
Nexvax2 placebo
Sodium chloride 0.9% intra-dermal injections twice weekly
Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)
Nexvax2 by ID injections for a total of 14 doses over 46 days.
Nexvax2
Nexvax2 intra-dermal injections twice weekly
Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)
Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
Nexvax2 placebo
Sodium chloride 0.9% intra-dermal injections twice weekly
Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)
Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
Nexvax2
Nexvax2 intra-dermal injections twice weekly
Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)
Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
Nexvax2 placebo
Sodium chloride 0.9% intra-dermal injections twice weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nexvax2
Nexvax2 intra-dermal injections twice weekly
Nexvax2 placebo
Sodium chloride 0.9% intra-dermal injections twice weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is between 18 and 70 years old (inclusive) on the date of the Screening Visit.
3. Subject has been diagnosed with celiac disease on the basis of intestinal histology showing villous atrophy according to expert guidelines current at the time of diagnosis.
4. Subject has HLA DQ2.5 genotype (HLA-DQA1\*05 and HLA-DQB1\*02).
Exclusion Criteria
2. Celiac Dietary Adherence Test at screening indicates non-compliance to gluten-free diet (score \>12).
3. Serum levels of both recombinant human transglutaminase (tTG)-specific immunoglobulin-A (IgA) and deamidated gliadin peptide (DGP)-specific immunoglobulin-G (IgG) are elevated above the manufacturer's upper limit of normal. The elevation of one or other of the serology test for tTG IgA and DGP IgG is not an exclusion.
4. Subject has uncontrolled complications of celiac disease or a medical condition which, in the opinion of the investigator, would impact the immune response or pose an increased risk to the subject.
5. Subject is or has been using an immuno-modulatory or immune suppressing medical treatment during the 2 months prior to Screening, for example azathioprine, methotrexate, or biological
6. Subject is female and premenopausal or perimenopausal and has a male partner who is not sterile, unless she is sterile, or she practices true abstinence, or unless throughout the entire study period and for 30 days after study drug discontinuation she is using a medically acceptable method of contraception.
7. Subject is male with a premenopausal or perimenopausal female partner who is not sterile, unless he is sterile, or he practices true abstinence, or unless throughout the entire study period and for 30 days after study drug discontinuation he is using a medically acceptable method of contraception, or unless his female partner is using a medically acceptable method of contraception.
8. Subject is unable and/or unwilling to comply with study requirements.
9. Subject has taken oral or parenteral corticosteroids within the previous six weeks prior to Screening. Topical or inhaled corticosteroids are acceptable.
10. Subject has received an experimental therapy within 30 days prior to Screening.
11. Subject has previously been enrolled and dosed in a clinical trial with Nevax2.
12. Subject has any of the following laboratory abnormalities at Screening:
* Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) ≥ 2 × the upper limit of normal (ULN)
* Hemoglobin \<10 g/dL
* Platelet count \<100 × 109/L
* White blood cell count (WBC) outside the normal range and judged clinically significant by the investigator
* Direct bilirubin outside the normal range
* Any other clinically significant abnormal laboratory values, as determined by the investigator
13. Subject is lactating, is known to be pregnant, has a positive pregnancy test at Screening or Treatment Day, intends to become pregnant, or is nursing.
14. Subject has a history or presence of any medically significant condition considered by the investigator to have the potential to adversely affect participation in the study and/or interpretation of the study results.
15. Subject has a history of severe allergic reactions (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that require medical intervention.
16. Subject has donated blood ≤ 56 days prior to Screening and plans to donate blood within 5 weeks after study completion.
17. Subject has a clinically relevant abnormality on electrocardiogram (ECG), as determined by the investigator.
18. Other unspecified reasons that in the opinion of the investigator or the sponsor make the subject unsuitable for enrollment.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmusanT, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert P. Anderson, MB ChB, PhD
Role: STUDY_CHAIR
ImmusanT, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Q-Pharm Pty Ltd.
Herston, Queensland, Australia
CMAX, A Division of IDT Australia Ltd
Adelaide, South Australia, Australia
Linear Clinical Research
Nedlands, , Australia
Auckland Clinical Studies Ltd
Auckland, , New Zealand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Daveson AJM, Ee HC, Andrews JM, King T, Goldstein KE, Dzuris JL, MacDougall JA, Williams LJ, Treohan A, Cooreman MP, Anderson RP. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. EBioMedicine. 2017 Dec;26:78-90. doi: 10.1016/j.ebiom.2017.11.018. Epub 2017 Nov 22.
Related Links
Access external resources that provide additional context or updates about the study.
MedlinePlus
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1173-7522
Identifier Type: OTHER
Identifier Source: secondary_id
Nexvax2-1004
Identifier Type: -
Identifier Source: org_study_id